

Paul M Barr

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7053054/publications.pdf>

Version: 2024-02-01

222
papers

11,574
citations

50276

46
h-index

30087

103
g-index

226
all docs

226
docs citations

226
times ranked

8791
citing authors

#	ARTICLE	IF	CITATIONS
1	Relevance of Bone Marrow Biopsies for Response Assessment in US National Cancer Institute National Clinical Trials Network Follicular Lymphoma Clinical Trials. <i>Journal of Clinical Oncology</i> , 2023, 41, 336-342.	1.6	9
2	Zilovetamab Vedotin Targeting of ROR1 as Therapy for Lymphoid Cancers. , 2022, 1, .		28
3	Fixed-duration ibrutinib plus venetoclax for first-line treatment of CLL: primary analysis of the CAPTIVATE FD cohort. <i>Blood</i> , 2022, 139, 3278-3289.	1.4	83
4	The highly selective Bruton tyrosine kinase inhibitor acalabrutinib leaves macrophage phagocytosis intact. <i>Haematologica</i> , 2022, 107, 1460-1465.	3.5	2
5	Characterization of low-grade arthralgia, myalgia, and musculoskeletal pain with ibrutinib therapy: pooled analysis of clinical trials in patients with chronic lymphocytic leukemia and mantle cell lymphoma. <i>Leukemia and Lymphoma</i> , 2022, 63, 1580-1588.	1.3	0
6	Phase 1/2 study of acalabrutinib and the PI3K delta inhibitor ACP-319 in relapsed/refractory B-cell Non-Hodgkin lymphoma. <i>Leukemia and Lymphoma</i> , 2022, 63, 1728-1732.	1.3	2
7	Up to 8-year follow-up from RESONATE-2: first-line ibrutinib treatment for patients with chronic lymphocytic leukemia. <i>Blood Advances</i> , 2022, 6, 3440-3450.	5.2	91
8	Long-term outcomes for ibrutinib+rituximab and chemoimmunotherapy in CLL: updated results of the E1912 trial. <i>Blood</i> , 2022, 140, 112-120.	1.4	93
9	Venetoclax retreatment of patients with chronic lymphocytic leukemia after a previous venetoclax-based regimen. <i>Blood Advances</i> , 2022, 6, 4553-4557.	5.2	22
10	Fixed-duration (FD) ibrutinib (I) + venetoclax (V) for first-line (1L) treatment (tx) of chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL): Three-year follow-up from the FD cohort of the phase 2 CAPTIVATE study.. <i>Journal of Clinical Oncology</i> , 2022, 40, 7519-7519.	1.6	4
11	Abstract CT028: Fixed-duration (FD) ibrutinib (Ibr) + venetoclax (Ven) for first-line treatment of chronic lymphocytic leukemia (CLL) in patients (pts) with high-risk features: phase 2 CAPTIVATE study. <i>Cancer Research</i> , 2022, 82, CT028-CT028.	0.9	0
12	Short term results of vaccination with adjuvanted recombinant varicella zoster glycoprotein E during initial BTK inhibitor therapy for CLL or lymphoplasmacytic lymphoma. <i>Leukemia</i> , 2021, 35, 1788-1791.	7.2	29
13	Phase 2 study of the safety and efficacy of umbralisib in patients with CLL who are intolerant to BTK or PI3K δ inhibitor therapy. <i>Blood</i> , 2021, 137, 2817-2826.	1.4	38
14	Toxicity patterns of novel PI3K combinations in patients with non-Hodgkin lymphoma. <i>Leukemia and Lymphoma</i> , 2021, 62, 598-605.	1.3	1
15	Fixed-duration (FD) first-line treatment (tx) with ibrutinib (I) plus venetoclax (V) for chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL): Primary analysis of the FD cohort of the phase 2 captivate study.. <i>Journal of Clinical Oncology</i> , 2021, 39, 7501-7501.	1.6	16
16	Up to seven years of follow-up in the RESONATE-2 study of first-line ibrutinib treatment for patients with chronic lymphocytic leukemia.. <i>Journal of Clinical Oncology</i> , 2021, 39, 7523-7523.	1.6	20
17	Brentuximab Vedotin Combined With Chemotherapy in Patients With Newly Diagnosed Early-Stage, Unfavorable-Risk Hodgkin Lymphoma. <i>Journal of Clinical Oncology</i> , 2021, 39, 2257-2265.	1.6	32
18	COVID-19 in patients with CLL: improved survival outcomes and update on management strategies. <i>Blood</i> , 2021, 138, 1768-1773.	1.4	53

#	ARTICLE	IF	CITATIONS
19	Using ibrutinib in earlier lines of treatment results in better outcomes for patients with chronic lymphocytic leukemia/small lymphocytic lymphoma. <i>Leukemia and Lymphoma</i> , 2021, 62, 3278-3282.	1.3	7
20	Measurable residual disease does not preclude prolonged progression-free survival in CLL treated with ibrutinib. <i>Blood</i> , 2021, 138, 2810-2827.	1.4	16
21	Phase II Study of Acalabrutinib and High-Frequency Low-Dose Subcutaneous Rituximab in Patients with Previously Untreated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL). <i>Blood</i> , 2021, 138, 2640-2640.	1.4	0
22	Highlights in leukemia and lymphoma from the 62nd American Society of Hematology Annual Meeting and Exposition: commentary. <i>Clinical Advances in Hematology and Oncology</i> , 2021, 19 Suppl 11, 17-19.	0.3	0
23	Long-term efficacy and safety of first-line ibrutinib treatment for patients with CLL/SLL: 5 years of follow-up from the phase 3 RESONATE-2 study. <i>Leukemia</i> , 2020, 34, 787-798.	7.2	321
24	The efficacy and safety of venetoclax therapy in elderly patients with relapsed, refractory chronic lymphocytic leukaemia. <i>British Journal of Haematology</i> , 2020, 188, 918-923.	2.5	19
25	Significant weight gain in CLL patients treated with Ibrutinib: A potentially deleterious consequence of therapy. <i>American Journal of Hematology</i> , 2020, 95, E16-E18.	4.1	2
26	Efficacy of lenalidomide in high-risk diffuse large B-cell lymphoma. <i>British Journal of Haematology</i> , 2020, 188, e33-e36.	2.5	6
27	Outcomes of COVID-19 in patients with CLL: a multicenter international experience. <i>Blood</i> , 2020, 136, 1134-1143.	1.4	248
28	Positron Emission Tomography-Directed Therapy for Patients With Limited-Stage Diffuse Large B-Cell Lymphoma: Results of Intergroup National Clinical Trials Network Study S1001. <i>Journal of Clinical Oncology</i> , 2020, 38, 3003-3011.	1.6	75
29	Efficacy of bendamustine and rituximab in unfit patients with previously untreated chronic lymphocytic leukemia. Indirect comparison with ibrutinib in a real-world setting. A GIMEMA-ERIC and US study. <i>Cancer Medicine</i> , 2020, 9, 8468-8479.	2.8	12
30	<p>The Impact of Age on Survival in CLL Patients Receiving Ibrutinib as Initial Therapy</p>. <i>Blood and Lymphatic Cancer: Targets and Therapy</i> , 2020, Volume 10, 1-5.	2.7	1
31	Additional B-cell malignancies in patients with chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL). <i>Leukemia and Lymphoma</i> , 2020, 61, 1636-1644.	1.3	1
32	Cognitive function in patients with chronic lymphocytic leukemia: a cross-sectional study examining effects of disease and treatment. <i>Leukemia and Lymphoma</i> , 2020, 61, 1627-1635.	1.3	11
33	Assessment of the Efficacy of Therapies Following Venetoclax Discontinuation in CLL Reveals BTK Inhibition as an Effective Strategy. <i>Clinical Cancer Research</i> , 2020, 26, 3589-3596.	7.0	80
34	A cross-trial comparison of single-agent ibrutinib versus chlorambucil-obinutuzumab in previously untreated patients with chronic lymphocytic leukemia or small lymphocytic lymphoma. <i>Haematologica</i> , 2020, 105, e164-e168.	3.5	5
35	Comparative analysis of targeted novel therapies in relapsed, refractory chronic lymphocytic leukaemia. <i>Haematologica</i> , 2020, 106, 284-287.	3.5	8
36	Early Progression of Follicular Lymphoma. <i>Hematology/Oncology Clinics of North America</i> , 2020, 34, 757-769.	2.2	2

#	ARTICLE	IF	CITATIONS
37	Initial treatment of B-cell prolymphocytic leukemia with ibrutinib. <i>American Journal of Hematology</i> , 2020, 95, E108-E110.	4.1	8
38	Complete recovery of late onset progressive multifocal leukoencephalopathy related to treatment with chemoimmunotherapy: A case report. <i>Leukemia Research</i> , 2020, 90, 106309.	0.8	3
39	A Phase 1/2 Study of Umbralisib, Ublituximab, and Venetoclax (U2-Ven) in Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL). <i>Blood</i> , 2020, 136, 41-42.	1.4	6
40	Venetoclax Re-Treatment of Chronic Lymphocytic Leukemia (CLL) Patients after a Previous Venetoclax-Based Regimen. <i>Blood</i> , 2020, 136, 39-41.	1.4	13
41	Ibrutinib Off-Target Inhibition Inhibits Antibody-Dependent Cellular Phagocytosis but Not Efferocytosis of CLL Cells. <i>Blood</i> , 2020, 136, 45-45.	1.4	4
42	Relevance of bone marrow biopsies for response assessment in NCTN follicular lymphoma clinical trials.. <i>Journal of Clinical Oncology</i> , 2020, 38, 8038-8038.	1.6	1
43	Mantle cell lymphoma: initial report from the North American Mantle Cell Lymphoma Consortium.. <i>Journal of Clinical Oncology</i> , 2020, 38, 8035-8035.	1.6	0
44	Real-world practice patterns in follicular lymphoma (FL) care at community oncology centers.. <i>Journal of Clinical Oncology</i> , 2020, 38, 231-231.	1.6	0
45	Arrhythmia Burden in Patients with Indolent Lymphoma. <i>Blood</i> , 2020, 136, 6-7.	1.4	1
46	Venetoclax Effectiveness, Safety, and Treatment Patterns in Chronic Lymphocytic Leukemia Patients: Results from the CLL Collaborative Study of Real-World Evidence (CORE). <i>Blood</i> , 2020, 136, 19-22.	1.4	0
47	A phase 1 trial of SGN-CD70A in patients with CD70-positive diffuse large B cell lymphoma and mantle cell lymphoma. <i>Investigational New Drugs</i> , 2019, 37, 297-306.	2.6	51
48	Nivolumab Combined With Brentuximab Vedotin for Relapsed/Refractory Primary Mediastinal Large B-Cell Lymphoma: Efficacy and Safety From the Phase II CheckMate 436 Study. <i>Journal of Clinical Oncology</i> , 2019, 37, 3081-3089.	1.6	120
49	Five-year follow-up of SWOG S0816: limitations and values of a PET-adapted approach with stage III/IV Hodgkin lymphoma. <i>Blood</i> , 2019, 134, 1238-1246.	1.4	86
50	Patients with diffuse large B-cell lymphoma requiring urgent treatment: its implication on trial design and interpretation. <i>Leukemia and Lymphoma</i> , 2019, 60, 3569-3572.	1.3	4
51	Long-Term Studies Assessing Outcomes of Ibrutinib Therapy in Patients With Del(11q) Chronic Lymphocytic Leukemia. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2019, 19, 715-722.e6.	0.4	35
52	Follicular Lymphoma: Recent and Emerging Therapies, Treatment Strategies, and Remaining Unmet Needs. <i>Oncologist</i> , 2019, 24, e1236-e1250.	3.7	36
53	Ibrutinib+Rituximab or Chemoimmunotherapy for Chronic Lymphocytic Leukemia. <i>New England Journal of Medicine</i> , 2019, 381, 432-443.	27.0	545
54	Final analysis from RESONATE: Up to six years of follow-up on ibrutinib in patients with previously treated chronic lymphocytic leukemia or small lymphocytic lymphoma. <i>American Journal of Hematology</i> , 2019, 94, 1353-1363.	4.1	305

#	ARTICLE	IF	CITATIONS
55	Nivolumab Combined with Brentuximab Vedotin (BV) for Relapsed/Refractory Primary Mediastinal Large B-Cell Lymphoma (R/R PMBL): Efficacy and Safety Results from the Phase 2 CheckMate 436 Study. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2019, 19, S303.	0.4	1
56	Five-Year Follow-Up After Ibrutinib Therapy for First-Line Treatment of Chronic Lymphocytic Leukemia. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2019, 19, S274.	0.4	0
57	How I treat early-relapsing follicular lymphoma. <i>Blood</i> , 2019, 133, 1540-1547.	1.4	33
58	Tumor Lysis, Adverse Events, and Dose Adjustments in 297 Venetoclax-Treated CLL Patients in Routine Clinical Practice. <i>Clinical Cancer Research</i> , 2019, 25, 4264-4270.	7.0	61
59	Multicentre retrospective study of intravascular large B-cell lymphoma treated at academic institutions within the United States. <i>British Journal of Haematology</i> , 2019, 186, 255-262.	2.5	17
60	Long-term follow-up of the RESONATE phase 3 trial of ibrutinib vs ofatumumab. <i>Blood</i> , 2019, 133, 2031-2042.	1.4	178
61	Utility of positron emission tomography-computed tomography in patients with chronic lymphocytic leukemia following B-cell receptor pathway inhibitor therapy. <i>Haematologica</i> , 2019, 104, 2258-2264.	3.5	26
62	Augmenting Indolent Lymphoma Treatment Options With the Combination of Lenalidomide and Rituximab. <i>Journal of Clinical Oncology</i> , 2019, 37, 1151-1153.	1.6	0
63	Ibrutinib provides favourable survival outcomes in patients with comorbidities <i>versus</i> established therapies. <i>British Journal of Haematology</i> , 2019, 186, 175-180.	2.5	9
64	Tumour debulking and reduction in predicted risk of tumour lysis syndrome with single-agent ibrutinib in patients with chronic lymphocytic leukaemia. <i>British Journal of Haematology</i> , 2019, 186, 184-188.	2.5	10
65	Outcomes with ibrutinib by line of therapy and post-ibrutinib discontinuation in patients with chronic lymphocytic leukemia: Phase 3 analysis. <i>American Journal of Hematology</i> , 2019, 94, 554-562.	4.1	27
66	Long-term safety of single-agent ibrutinib in patients with chronic lymphocytic leukemia in 3 pivotal studies. <i>Blood Advances</i> , 2019, 3, 1799-1807.	5.2	90
67	A retrospective comparison of venetoclax alone or in combination with an anti-CD20 monoclonal antibody in R/R CLL. <i>Blood Advances</i> , 2019, 3, 1568-1573.	5.2	26
68	Five-year outcomes of the S1106 study of R-hyper-CVAD vs R-bendamustine in transplant-eligible patients with mantle cell lymphoma. <i>Blood Advances</i> , 2019, 3, 3132-3135.	5.2	18
69	Venetoclax for chronic lymphocytic leukaemia patients who progress after more than one B-cell receptor pathway inhibitor. <i>British Journal of Haematology</i> , 2019, 185, 961-966.	2.5	12
70	Ibrutinib Dose Adherence and Therapeutic Efficacy in Non-Hodgkin Lymphoma: A Single-Center Experience. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2019, 19, 41-47.	0.4	19
71	Ibrutinib (Ibr) Plus Venetoclax (Ven) for First-Line Treatment of Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL): Results from the MRD Cohort of the Phase 2 CAPTIVATE Study. <i>Blood</i> , 2019, 134, 35-35.	1.4	40
72	Utilization and Early Discontinuation of First-Line Ibrutinib for Patients with Chronic Lymphocytic Leukemia Treated in the Community Oncology Setting in the United States. <i>Blood</i> , 2019, 134, 797-797.	1.4	4

#	ARTICLE	IF	CITATIONS
73	A Pilot Study of Brentuximab Vedotin Combined with AVD Chemotherapy and Radiotherapy in Patients with Newly Diagnosed Early Stage, Unfavorable Risk Hodgkin Lymphoma. <i>Blood</i> , 2019, 134, 2834-2834.	1.4	1
74	A Phase 1/2 Study of Umbralisib Ublituximab and Venetoclax in Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL). <i>Blood</i> , 2019, 134, 360-360.	1.4	11
75	Efficacy of Therapies Following Venetoclax Discontinuation in CLL: Focus on B-Cell Receptor Signal Transduction Inhibitors and Cellular Therapies. <i>Blood</i> , 2019, 134, 502-502.	1.4	4
76	PET-Directed Therapy for Patients with Limited-Stage Diffuse Large B-Cell Lymphoma - Results of InterGroup Nctn Study S1001. <i>Blood</i> , 2019, 134, 349-349.	1.4	13
77	Treatment Sequences and Outcomes of Patients with CLL Treated with Venetoclax and Other Novel Agents Post Introduction of Novel Therapies. <i>Blood</i> , 2019, 134, 1756-1756.	1.4	1
78	Anti-CD20 Therapy Reliance on Antibody-Dependent Cellular Phagocytosis Affects Combination Drug Choice. <i>Blood</i> , 2019, 134, 682-682.	1.4	1
79	Ibrutinib and Rituximab Provides Superior Clinical Outcome Compared to FCR in Younger Patients with Chronic Lymphocytic Leukemia (CLL): Extended Follow-up from the E1912 Trial. <i>Blood</i> , 2019, 134, 33-33.	1.4	29
80	Final analysis from RESONATE: Six-year follow-up in patients (pts) with previously treated chronic lymphocytic leukemia or small lymphocytic lymphoma (CLL/SLL) on ibrutinib.. <i>Journal of Clinical Oncology</i> , 2019, 37, 7510-7510.	1.6	1
81	Cognitive function in chronic lymphocytic leukemia (CLL): Examining effects of disease, treatment, and inflammation.. <i>Journal of Clinical Oncology</i> , 2019, 37, 11584-11584.	1.6	2
82	Outcomes of lenalidomide in diffuse large B-cell (DLBCL) and high-grade NHL (HGBCL): A single-center retrospective analysis.. <i>Journal of Clinical Oncology</i> , 2019, 37, 7547-7547.	1.6	0
83	High risk patients with diffuse large B cell lymphoma are not enrolled on clinical trials.. <i>Journal of Clinical Oncology</i> , 2019, 37, e19058-e19058.	1.6	0
84	Using Ibrutinib in Earlier Lines of Treatment Results in Better Outcomes for Patients with Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma. <i>Blood</i> , 2019, 134, 3054-3054.	1.4	2
85	Treatment Discontinuation Patterns for Patients with CLL in the Real-World Settings: Results from a Multi-Center Study. <i>Blood</i> , 2019, 134, 3048-3048.	1.4	0
86	Toxicities and outcomes of 616 ibrutinib-treated patients in the United States: a real-world analysis. <i>Haematologica</i> , 2018, 103, 874-879.	3.5	329
87	R-CHOP, radioimmunotherapy, and maintenance rituximab in untreated follicular lymphoma (SWOG) Tj ETQq1 1 0.784314 rgBT /Ove	4.6	20
88	Phase 1 study of the PI3KÎ inhibitor INCB040093 ± JAK1 inhibitor itacitinib in relapsed/refractory B-cell lymphoma. <i>Blood</i> , 2018, 132, 293-306.	1.4	45
89	Analysis of the risk of infection in patients with chronic lymphocytic leukemia in the era of novel therapies. <i>Leukemia and Lymphoma</i> , 2018, 59, 625-632.	1.3	57
90	Venetoclax for chronic lymphocytic leukaemia progressing after ibrutinib: an interim analysis of a multicentre, open-label, phase 2 trial. <i>Lancet Oncology</i> , The, 2018, 19, 65-75.	10.7	314

#	ARTICLE	IF	CITATIONS
91	Ibrutinib Regimens versus Chemoimmunotherapy in Older Patients with Untreated CLL. <i>New England Journal of Medicine</i> , 2018, 379, 2517-2528.	27.0	706
92	Complications Associated With Dose-adjusted EPOCH-rituximab Therapy for Non-Hodgkin Lymphoma. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2018, 18, 781-787.	0.4	8
93	Pitfalls of Combining Novel Agents in Lymphoma. <i>Current Treatment Options in Oncology</i> , 2018, 19, 35.	3.0	1
94	Safety Analysis of Four Randomized Controlled Studies of Ibrutinib in Patients With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma or Mantle Cell Lymphoma. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2018, 18, 648-657.e15.	0.4	62
95	Management of melanoma in patients with chronic lymphocytic leukemia. <i>Leukemia Research</i> , 2018, 71, 43-46.	0.8	17
96	Survival adjusting for crossover: phase 3 study of ibrutinib vs chlorambucil in older patients with untreated chronic lymphocytic leukemia/small lymphocytic lymphoma. <i>Haematologica</i> , 2018, 103, e249-e251.	3.5	5
97	Outcomes of front-line ibrutinib treated CLL patients excluded from landmark clinical trial. <i>American Journal of Hematology</i> , 2018, 93, 1394-1401.	4.1	52
98	Cellular Cytotoxicity of Next-Generation CD20 Monoclonal Antibodies. <i>Cancer Immunology Research</i> , 2018, 6, 1150-1160.	3.4	57
99	Single-agent ibrutinib versus chemoimmunotherapy regimens for treatment-naïve patients with chronic lymphocytic leukemia: A cross-trial comparison of phase 3 studies. <i>American Journal of Hematology</i> , 2018, 93, 1402-1410.	4.1	24
100	Sustained efficacy and detailed clinical follow-up of first-line ibrutinib treatment in older patients with chronic lymphocytic leukemia: extended phase 3 results from RESONATE-2. <i>Haematologica</i> , 2018, 103, 1502-1510.	3.5	111
101	Real-world outcomes and management strategies for venetoclax-treated chronic lymphocytic leukemia patients in the United States. <i>Haematologica</i> , 2018, 103, 1511-1517.	3.5	135
102	Single-Agent Ibrutinib Versus Chlorambucil-Obinutuzumab As First-Line Treatment in Patients with Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma (CLL/SLL): Results of a Cross-Trial Comparison. <i>Blood</i> , 2018, 132, 5565-5565.	1.4	3
103	Nivolumab Combined with Brentuximab Vedotin for Relapsed/Refractory Primary Mediastinal Large B-Cell Lymphoma: Preliminary Results from the Phase 2 CheckMate 436 Trial. <i>Blood</i> , 2018, 132, 1691-1691.	1.4	4
104	Long-Term Follow-up of SWOG S0816: Response-Adapted Therapy for Stage III/IV Hodgkin Lymphoma Demonstrates Limitations of PET-Adapted Approach. <i>Blood</i> , 2018, 132, 929-929.	1.4	6
105	Venetoclax As Monotherapy or in Combination: Patterns of Use and Predictors of Outcomes in an International Multicenter Study of CLL Patients. <i>Blood</i> , 2018, 132, 3142-3142.	1.4	2
106	Ibrutinib Alone or in Combination with Rituximab Produces Superior Progression Free Survival (PFS) Compared with Bendamustine Plus Rituximab in Untreated Older Patients with Chronic Lymphocytic Leukemia (CLL): Results of Alliance North American Intergroup Study A041202. <i>Blood</i> , 2018, 132, 6-6.	1.4	18
107	Acalabrutinib combined with PI3K inhibitor ACP-319 in patients (pts) with relapsed/refractory (R/R) B-cell malignancies.. <i>Journal of Clinical Oncology</i> , 2018, 36, 7518-7518.	1.6	6
108	A phase 2 study to assess the safety and efficacy of umbralisib (TGR-1202) in pts with CLL who are intolerant to prior BTK or PI3K inhibitor therapy.. <i>Journal of Clinical Oncology</i> , 2018, 36, 7530-7530.	1.6	5

#	ARTICLE	IF	CITATIONS
109	Correlates of anxiety and depression in chronic lymphocytic leukemia (CLL) survivors.. Journal of Clinical Oncology, 2018, 36, 153-153.	1.6	3
110	Racial, age, and sex disparities in chronic lymphocytic leukemia (CLL) patients treated with novel therapies.. Journal of Clinical Oncology, 2018, 36, 6577-6577.	1.6	0
111	Prognostic role of beta-2 microglobulin (B2M) in relapsed/refractory (R/R) chronic lymphocytic leukemia (CLL) patients (pts) treated with ibrutinib (ibr).. Journal of Clinical Oncology, 2018, 36, 7521-7521.	1.6	0
112	Five-Year Outcomes of SWOG S1106: A Randomized Phase II US Intergroup Study of R-HCVAD Vs. R-Bendamustine Followed By Autologous Stem Cell Transplant for Patients with Mantle Cell Lymphoma. Blood, 2018, 132, 1593-1593.	1.4	0
113	Treatment Patterns and Outcomes of Patients with CLL Treated with Chemoimmuno- and Novel Agent-Based Therapy: A Multicenter Study. Blood, 2018, 132, 4759-4759.	1.4	1
114	Recommendations for Clinical Trial Development in Follicular Lymphoma. Journal of the National Cancer Institute, 2017, 109, djw255.	6.3	23
115	Late Relapses After High-dose Chemotherapy and Autologous Stem Cell Transplantation in Patients With Diffuse Large B-cell Lymphoma in the Rituximab Era. Clinical Lymphoma, Myeloma and Leukemia, 2017, 17, 145-151.	0.4	9
116	Use of anticoagulants and antiplatelet in patients with chronic lymphocytic leukaemia treated with single-agent ibrutinib. British Journal of Haematology, 2017, 178, 286-291.	2.5	55
117	Efficacy in the margins of NHL with ibrutinib. Blood, 2017, 129, 2207-2208.	1.4	0
118	Long-term safety experience with bendamustine for injection in a real-world setting. Expert Opinion on Drug Safety, 2017, 16, 647-650.	2.4	2
119	Treatment of chronic lymphocytic leukemia in older adults. Journal of Geriatric Oncology, 2017, 8, 315-319.	1.0	11
120	Impact of ibrutinib dose adherence on therapeutic efficacy in patients with previously treated CLL/SLL. Blood, 2017, 129, 2612-2615.	1.4	111
121	Idelalisib is effective in patients with high-risk follicular lymphoma and early relapse after initial chemoimmunotherapy. Blood, 2017, 129, 3037-3039.	1.4	68
122	Chemotherapy-free treatment in non-Hodgkin lymphoma: a steep learning curve. Lancet Haematology, 2017, 4, e152-e153.	4.6	1
123	RB but not R-HCVAD is a feasible induction regimen prior to auto-HCT in frontline MCL: results of SWOG Study S1106. British Journal of Haematology, 2017, 176, 759-769.	2.5	40
124	Tumor Debulking and Reduction in Risk of Tumor Lysis Syndrome with Single-Agent Ibrutinib. Clinical Lymphoma, Myeloma and Leukemia, 2017, 17, S304.	0.4	0
125	Understanding the New WHO Classification of Lymphoid Malignancies: Why It's Important and How It Will Affect Practice. American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting, 2017, 37, 535-546.	3.8	29
126	Abstract CT158: Unmutated IGHV is not an adverse predictor of outcome to therapy with ibrutinib in patients with chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL)., 2017, .		2

#	ARTICLE	IF	CITATIONS
127	Long-term efficacy and safety with ibrutinib (ibr) in previously treated chronic lymphocytic leukemia (CLL): Up to four years follow-up of the RESONATE study.. Journal of Clinical Oncology, 2017, 35, 7510-7510.	1.6	11
128	Understanding the New WHO Classification of Lymphoid Malignancies: Why It's Important and How It Will Affect Practice. American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting, 2017, 37, 535-546.	3.8	19
129	Phase I clinical trial of the base excision repair inhibitor methoxyamine in combination with fludarabine for patients with advanced hematologic malignancies. Oncotarget, 2017, 8, 79864-79875.	1.8	15
130	KI intolerance study: A phase 2 study to assess the safety and efficacy of TGR-1202 in pts with chronic lymphocytic leukemia (CLL) who are intolerant to prior BTK or PI3K-delta inhibitor therapy.. Journal of Clinical Oncology, 2017, 35, TPS7569-TPS7569.	1.6	0
131	Central line-associated complications during treatment with DA-R-EPOCH therapy for NHL.. Journal of Clinical Oncology, 2017, 35, 7543-7543.	1.6	1
132	Enrollment of high-risk patients with diffuse large B-cell lymphoma in clinical trials.. Journal of Clinical Oncology, 2017, 35, 6536-6536.	1.6	0
133	CheckMate 436: A phase 1-2 study to evaluate safety and efficacy of nivolumab plus brentuximab vedotin in patients with CD30-expressing relapsed/refractory non-Hodgkin lymphomas.. Journal of Clinical Oncology, 2017, 35, TPS7577-TPS7577.	1.6	0
134	Deregulation of NF- κ B, ie, a useful PMBL marker. Blood, 2016, 128, 2591-2592.	1.4	4
135	Outcomes of CLL patients treated with sequential kinase inhibitor therapy: a real world experience. Blood, 2016, 128, 2199-2205.	1.4	166
136	Consolidative Radioimmunotherapy After Chemoimmunotherapy in Patients With Histologic Transformation of Indolent Non-Hodgkin Lymphoma. Clinical Lymphoma, Myeloma and Leukemia, 2016, 16, 322-328.e2.	0.4	5
137	US Intergroup Trial of Response-Adapted Therapy for Stage III to IV Hodgkin Lymphoma Using Early Interim Fluorodeoxyglucose- α Positron Emission Tomography Imaging: Southwest Oncology Group S0816. Journal of Clinical Oncology, 2016, 34, 2020-2027.	1.6	239
138	Phase 2 study of idelalisib and entospletinib: pneumonitis limits combination therapy in relapsed refractory CLL and NHL. Blood, 2016, 127, 2411-2415.	1.4	131
139	Clinicogenetic risk models predict early progression of follicular lymphoma after first-line immunochemotherapy. Blood, 2016, 128, 1112-1120.	1.4	177
140	Postibrutinib outcomes in patients with mantle cell lymphoma. Blood, 2016, 127, 1559-1563.	1.4	228
141	Outpatient administration of BEAM conditioning prior to autologous stem cell transplantation for lymphoma is safe, feasible, and cost-effective. Cancer Medicine, 2016, 5, 3059-3067.	2.8	18
142	Phase I study of single-agent CC-292, a highly selective Brutons tyrosine kinase inhibitor, in relapsed/refractory chronic lymphocytic leukemia. Haematologica, 2016, 101, e295-e298.	3.5	67
143	Brentuximab vedotin and AVD followed by involved-site radiotherapy in early stage, unfavorable risk Hodgkin lymphoma. Blood, 2016, 128, 1458-1464.	1.4	61
144	Survival of Secondary Central Nervous System Lymphoma Patients in the Rituximab Era. Clinical Lymphoma, Myeloma and Leukemia, 2016, 16, e123-e127.	0.4	5

#	ARTICLE	IF	CITATIONS
145	Phase 1 trial of carfilzomib (PR-171) in combination with vorinostat (SAHA) in patients with relapsed or refractory B-cell lymphomas. <i>Leukemia and Lymphoma</i> , 2016, 57, 635-643.	1.3	21
146	Outcomes of Ibrutinib Therapy By Age in Patients with CLL/SLL: Analyses from Phase 3 Trial Data (RESONATE and RESONATE-2). <i>Blood</i> , 2016, 128, 2041-2041.	1.4	4
147	11q Deletion (del11q) Is Not a Prognostic Factor for Adverse Outcomes for Patients with Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) Treated with Ibrutinib: Pooled Data from 3 Randomized Phase 3 Studies. <i>Blood</i> , 2016, 128, 2042-2042.	1.4	9
148	Updated Efficacy and Safety from the Phase 3 Resonate-2 Study: Ibrutinib As First-Line Treatment Option in Patients 65 Years and Older with Chronic Lymphocytic Leukemia/Small Lymphocytic Leukemia. <i>Blood</i> , 2016, 128, 234-234.	1.4	36
149	High Risk of Infections in Chronic Lymphocytic Leukemia Patients Treated with B-Cell Receptor Inhibitors. <i>Blood</i> , 2016, 128, 3203-3203.	1.4	2
150	Toxicities and Outcomes of Ibrutinib-Treated Patients in the United States: Large Retrospective Analysis of 621 Real World Patients. <i>Blood</i> , 2016, 128, 3222-3222.	1.4	16
151	A Retrospective Analysis of <i>Pneumocystis Jirovecii</i> Pneumonia Infection in Patients Receiving Idelalisib in Clinical Trials. <i>Blood</i> , 2016, 128, 3705-3705.	1.4	23
152	Integrated and Long-Term Safety Analysis of Ibrutinib in Patients with Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL). <i>Blood</i> , 2016, 128, 4383-4383.	1.4	7
153	Optimal Sequencing of Ibrutinib, Idelalisib, and Venetoclax in CLL: Results from a Large Multi-Center Study of 683 US-Patients. <i>Blood</i> , 2016, 128, 4400-4400.	1.4	2
154	Venetoclax (VEN) Monotherapy for Patients with Chronic Lymphocytic Leukemia (CLL) Who Relapsed after or Were Refractory to Ibrutinib or Idelalisib. <i>Blood</i> , 2016, 128, 637-637.	1.4	48
155	Venetoclax activity in CLL patients who have relapsed after or are refractory to ibrutinib or idelalisib.. <i>Journal of Clinical Oncology</i> , 2016, 34, 7519-7519.	1.6	11
156	Outcomes with ibrutinib by line of therapy in patients with CLL: Analyses from phase III data.. <i>Journal of Clinical Oncology</i> , 2016, 34, 7520-7520.	1.6	10
157	A phase 1/2 study to evaluate safety and efficacy of nivolumab plus brentuximab vedotin in patients with CD30-expressing relapsed/refractory non-Hodgkin lymphomas (NHLs).. <i>Journal of Clinical Oncology</i> , 2016, 34, TPS7576-TPS7576.	1.6	1
158	Sequential RCHOP, Radioimmunotherapy and Rituximab Maintenance Improves Early Outcomes in Advanced Stage Follicular Lymphoma: 5 Year Outcomes from SWOG 0801. <i>Blood</i> , 2016, 128, 614-614.	1.4	0
159	Long-Term Safety Experience with Bendamustine for Injection in a Real-World Setting. <i>Blood</i> , 2016, 128, 5591-5591.	1.4	0
160	The Bruton tyrosine kinase inhibitor ibrutinib with chemoimmunotherapy in patients with chronic lymphocytic leukemia. <i>Blood</i> , 2015, 125, 2915-2922.	1.4	104
161	Ibrutinib as Initial Therapy for Patients with Chronic Lymphocytic Leukemia. <i>New England Journal of Medicine</i> , 2015, 373, 2425-2437.	27.0	1,261
162	Impact of dietary supplements, obesity and treatment initiation on serum vitamin D levels in patients with lymphoma. <i>Leukemia and Lymphoma</i> , 2015, 56, 508-511.	1.3	3

#	ARTICLE	IF	CITATIONS
163	Phase II Intergroup Trial of Alisertib in Relapsed and Refractory Peripheral T-Cell Lymphoma and Transformed Mycosis Fungoides: SWOG 1108. <i>Journal of Clinical Oncology</i> , 2015, 33, 2399-2404.	1.6	97
164	Targeting B cell receptor signaling with ibrutinib in diffuse large B cell lymphoma. <i>Nature Medicine</i> , 2015, 21, 922-926.	30.7	927
165	Recent advances in the development of Aurora kinases inhibitors in hematological malignancies. <i>Therapeutic Advances in Hematology</i> , 2015, 6, 282-294.	2.5	10
166	Ibrutinib Versus Ofatumumab in Previously Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL): Results From the Randomized Phase III RESONATE [®] , [®] (PCYC-1112) Trial. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2015, 15, S204.	0.4	1
167	Adherence To The Ibrutinib 420 mg Dose Administered To Patients With Previously Treated CLL. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2015, 15, S24.	0.4	0
168	Activity of Idelalisib in High-Risk Follicular Lymphoma with Early Relapse Following Front Line Immunochemotherapy. <i>Blood</i> , 2015, 126, 2744-2744.	1.4	8
169	A Phase I/II Trial of Vorinostat (SAHA) in Combination with Rituximab-CHOP in Patients with Newly Diagnosed Advanced Stage Diffuse Large B-Cell Lymphoma (DLBCL): SWOG S0806. <i>Blood</i> , 2015, 126, 3931-3931.	1.4	4
170	Pre-Transplant R-Bendamustine Induces High Rates of Minimal Residual Disease in MCL Patients: Updated Results of S1106: US Intergroup Study of a Randomized Phase II Trial of R-HCVAD Vs. R-Bendamustine Followed By Autologous Stem Cell Transplants for Patients with Mantle Cell Lymphoma. <i>Blood</i> , 2015, 126, 518-518.	1.4	5
171	Preliminary Results of a Phase 2, Open-Label Study of Venetoclax (ABT-199/GDC-0199) Monotherapy in Patients with Chronic Lymphocytic Leukemia Relapsed after or Refractory to Ibrutinib or Idelalisib Therapy. <i>Blood</i> , 2015, 126, 715-715.	1.4	26
172	Favorable Outcomes in CLL Pts with Alternate Kinase Inhibitors Following Ibrutinib or Idelalisib Discontinuation: Results from a Large Multi-Center Study. <i>Blood</i> , 2015, 126, 719-719.	1.4	10
173	Interim analysis of a phase I study of INCB040093, a PI3K ^Î inhibitor, alone or in combination with INCB039110, a selective JAK1 inhibitor, in patients (pts) with relapsed or refractory (r/r) B-cell malignancies.. <i>Journal of Clinical Oncology</i> , 2015, 33, 8520-8520.	1.6	6
174	A phase 1 study of INCB040093, a PI3K ^Î inhibitor, alone or in combination with INCB039110, a selective JAK1 inhibitor: Interim results from patients (pts) with relapsed or refractory (r/r) classical Hodgkin lymphoma (cHL).. <i>Journal of Clinical Oncology</i> , 2015, 33, 8558-8558.	1.6	9
175	A phase 2 trial of INCB040093 alone or in combination with INCB039110 in patients (pts) with relapsed or refractory (r/r) classical Hodgkin lymphoma (cHL).. <i>Journal of Clinical Oncology</i> , 2015, 33, TPS8607-TPS8607.	1.6	1
176	Infection in chronic lymphocytic leukemia: parsimony has its limits. <i>Leukemia and Lymphoma</i> , 2014, 55, 2683-2684.	1.3	0
177	Emerging protein kinase inhibitors for the treatment of non-Hodgkin ^â ™s lymphoma. <i>Expert Opinion on Emerging Drugs</i> , 2014, 19, 367-383.	2.4	4
178	The ABC of chronic lymphocytic leukemia: Etiology of cytopenias is important in staging and management. <i>Leukemia and Lymphoma</i> , 2014, 55, 1219-1220.	1.3	0
179	Ibrutinib versus Ofatumumab in Previously Treated Chronic Lymphoid Leukemia. <i>New England Journal of Medicine</i> , 2014, 371, 213-223.	27.0	1,427
180	Crizotinib as Salvage and Maintenance With Allogeneic Stem Cell Transplantation for Refractory Anaplastic Large Cell Lymphoma. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2014, 12, 323-326.	4.9	22

#	ARTICLE	IF	CITATIONS
181	Phase 2 study of imexon, a prooxidant molecule, in relapsed and refractory B-cell non-Hodgkin lymphoma. <i>Blood</i> , 2014, 124, 1259-1265.	1.4	34
182	Pattern of Use of Anticoagulation and/or Antiplatelet Agents in Patients with Chronic Lymphocytic Leukemia (CLL) Treated with Single-Agent Ibrutinib Therapy. <i>Blood</i> , 2014, 124, 1990-1990.	1.4	10
183	Updated Efficacy Including Genetic and Clinical Subgroup Analysis and Overall Safety in the Phase 3 RESONATE™ Trial of Ibrutinib Versus Ofatumumab in Previously Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma. <i>Blood</i> , 2014, 124, 3331-3331.	1.4	24
184	Outpatient Administration of High Dose BEAM Chemotherapy As Conditioning for Autologous Stem Cell Transplantation for Lymphoma Results in Fewer Infectious Complications and Improved Survival. <i>Blood</i> , 2014, 124, 3984-3984.	1.4	1
185	Clinical Features, Treatment, and Survival of Secondary Central Nervous System Lymphoma. <i>Blood</i> , 2014, 124, 5389-5389.	1.4	4
186	Phase 2 trial of GS-9973, a selective syk inhibitor, and idelalisib (idela) in chronic lymphocytic leukemia (CLL) and non-Hodgkin lymphoma (NHL).. <i>Journal of Clinical Oncology</i> , 2014, 32, 7059-7059.	1.6	9
187	U.S. Intergroup phase II trial (SWOG 1108) of alisertib, an investigational aurora A kinase (AAK) inhibitor, in patients with peripheral T-cell lymphoma (PTCL; NCT01466881).. <i>Journal of Clinical Oncology</i> , 2014, 32, 8523-8523.	1.6	4
188	Adult Burkitt Lymphoma and Leukemia. , 2014, , 171-194.		0
189	Late Relapses Following High Dose Chemotherapy and Autologous Stem Cell Transplant in Patients with Diffuse Large B Cell Lymphoma in the Rituximab Era. <i>Blood</i> , 2014, 124, 3999-3999.	1.4	0
190	Consolidative Radioimmunotherapy after Chemoimmunotherapy in Patients with Histologic Transformation of Indolent Lymphoma. <i>Blood</i> , 2014, 124, 1746-1746.	1.4	0
191	Flavopiridol: Judged by the company one keeps. <i>Leukemia Research</i> , 2013, 37, 1187-1188.	0.8	2
192	A multicenter phase II study incorporating high-dose rituximab and liposomal doxorubicin into the CODOX-M/IVAC regimen for untreated Burkitt's lymphoma. <i>Annals of Oncology</i> , 2013, 24, 3076-3081.	1.2	45
193	Fostamatinib inhibits B-cell receptor signaling, cellular activation and tumor proliferation in patients with relapsed and refractory chronic lymphocytic leukemia. <i>Leukemia</i> , 2013, 27, 1769-1773.	7.2	49
194	Phase 1 Study Of Single Agent CC-292, a Highly Selective Bruton's Tyrosine Kinase (BTK) Inhibitor, In Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL). <i>Blood</i> , 2013, 122, 1630-1630.	1.4	29
195	Ibrutinib In Combination With Bendamustine and Rituximab Is Active and Tolerable In Patients With Relapsed/Refractory CLL/SLL: Final Results Of a Phase 1b Study. <i>Blood</i> , 2013, 122, 525-525.	1.4	32
196	Abstract 3531: Changes in immune cell populations in relapsed/refractory CLL patients treated with a Bruton's Tyrosine Kinase (BTK) Inhibitor, Ibrutinib (PCI-32765), in combination with Bendamustine and Rituximab (BR).. , 2013, , .		1
197	Redox Associated Gene Expression Predicts For Responses To The Pro-Oxidant Molecule Imexon In Relapsed and Refractory B-Cell Non-Hodgkin Lymphoma: Results Of a Multi-Center Phase II Study. <i>Blood</i> , 2013, 122, 89-89.	1.4	0
198	Outcome of patients with relapsed/refractory acquired immune deficiency syndrome-related lymphoma diagnosed 1999-2008 and treated with curative intent in the AIDS Malignancy Consortium. <i>Leukemia and Lymphoma</i> , 2012, 53, 2383-2389.	1.3	23

#	ARTICLE	IF	CITATIONS
199	Novel agents in mantle cell lymphoma. Best Practice and Research in Clinical Haematology, 2012, 25, 191-200.	1.7	3
200	Syk inhibition with fostamatinib leads to transitional B lymphocyte depletion. Clinical Immunology, 2012, 142, 237-242.	3.2	21
201	A Phase 2 Clinical Trial Adding Rituximab to CODOX-M/IVAC for Untreated Burkitts Lymphoma: Correlative Analysis of Serum and CSF Rituximab Levels. Blood, 2012, 120, 1640-1640.	1.4	1
202	The Bruton's Tyrosine Kinase (BTK) Inhibitor, Ibrutinib (PCI-32765), Has Preferential Activity in the ABC Subtype of Relapsed/Refractory De Novo Diffuse Large B-Cell Lymphoma (DLBCL): Interim Results of a Multicenter, Open-Label, Phase 2 Study. Blood, 2012, 120, 686-686.	1.4	99
203	Combination of the Bruton's tyrosine kinase (BTK) inhibitor PCI-32765 with bendamustine (B)/rituximab (R) (BR) in patients (pts) with relapsed/refractory (R/R) chronic lymphocytic leukemia (CLL): Interim results of a phase Ib/II study.. Journal of Clinical Oncology, 2012, 30, 6515-6515.	1.6	19
204	Phase Ib trial of AVL-292, a covalent inhibitor of Bruton's tyrosine kinase (Btk), in chronic lymphocytic leukemia (CLL) and B-non-Hodgkin lymphoma (B-NHL).. Journal of Clinical Oncology, 2012, 30, 8032-8032.	1.6	13
205	The incorporation of rituximab (R) and liposomal doxorubicin (LD) into CODOX-m/IVAC for untreated Burkitt lymphoma (BL): Final results of a prospective multicenter phase II study.. Journal of Clinical Oncology, 2012, 30, 8080-8080.	1.6	0
206	Fostamatinib Inhibits BCR Signaling, and Reduces Tumor Cell Activation and Proliferation in Patients with Relapsed Refractory Chronic Lymphocytic Leukemia.. Blood, 2012, 120, 2882-2882.	1.4	0
207	Getting to the heart of the problem in treating diffuse large B-cell lymphoma. Leukemia and Lymphoma, 2011, 52, 1166-1167.	1.3	0
208	Spontaneous Autologous Graft-versus-Host Disease in Plasma Cell Myeloma Autograft Recipients: Flow Cytometric Analysis of Hematopoietic Progenitor Cell Grafts. Biology of Blood and Marrow Transplantation, 2011, 17, 970-978.	2.0	42
209	Regression of CD30+ cutaneous anaplastic large-cell lymphoma with denileukin diftitox. Journal of the American Academy of Dermatology, 2011, 64, e123-e125.	1.2	3
210	Safety and tolerability of phase I/II clinical trials among older and younger patients with acute myelogenous leukemia. Journal of Geriatric Oncology, 2011, 2, 215-221.	1.0	8
211	Pneumocystis jirovecii pneumonia as a complication of bendamustine in a patient receiving bendamustine plus rituximab for marginal zone lymphoma. Leukemia Research, 2011, 35, e223-e224.	0.8	18
212	Pharmacology of Acute Lymphoblastic Leukemia Therapy. , 2011, , 127-144.		0
213	Correlation between ZAP70, phospho-ZAP70, and phospho-Syk expression in leukemic cells from patients with CLL. Cytometry Part B - Clinical Cytometry, 2010, 78B, 115-122.	1.5	7
214	Inhibition of Lck enhances glucocorticoid sensitivity and apoptosis in lymphoid cell lines and in chronic lymphocytic leukemia. Cell Death and Differentiation, 2010, 17, 1381-1391.	11.2	54
215	Non-Hodgkin's Lymphoma in the Elderly. Drugs and Aging, 2010, 27, 211-238.	2.7	7
216	Targeting Bcl-2 based on the interaction of its BH4 domain with the inositol 1,4,5-trisphosphate receptor. Biochimica Et Biophysica Acta - Molecular Cell Research, 2009, 1793, 971-978.	4.1	63

#	ARTICLE	IF	CITATIONS
217	Phase II study of bryostatin 1 and vincristine for aggressive non-Hodgkin lymphoma relapsing after an autologous stem cell transplant. <i>American Journal of Hematology</i> , 2009, 84, 484-487.	4.1	62
218	Phase I trial of fludarabine, bortezomib and rituximab for relapsed and refractory indolent and mantle cell non-Hodgkin lymphoma. <i>British Journal of Haematology</i> , 2009, 147, 89-96.	2.5	22
219	Follicular non-Hodgkin lymphoma: long-term results of stem-cell transplantation. <i>Current Opinion in Oncology</i> , 2008, 20, 502-508.	2.4	10
220	Antiangiogenic activity of thalidomide in combination with fludarabine, carboplatin, and topotecan for high-risk acute myelogenous leukemia. <i>Leukemia and Lymphoma</i> , 2007, 48, 1940-1949.	1.3	17
221	The Role of Bortezomib in the Treatment of Lymphoma. <i>Cancer Investigation</i> , 2007, 25, 766-775.	1.3	29
222	Adenosine depresses transmitter release but is not the basis for 'tetanic fade' at the neuromuscular junction of the rat. <i>Neuroscience Letters</i> , 1997, 230, 81-84.	2.1	13